Kia ora John,

 

I am Sean from the data services team at the Ministry of Health, and I
will do my best to help with this query.

We are the team responsible for extracting data from the national
collections (including the pharmaceutical collection). We discussed your
request with the OIA team and agreed that it would be best to treat this
as a usual data request as it would be nice to get some more information
from you.

 

I should mention that the Ministry of Health has no access to primary
healthcare data so we have no way to identify if an individual has with
Crohn's disease of ulcerative colitis, the only possible way to identify
people with this condition would be if an individual had been hospitalised
for it (and it is my understanding that this would definitely undercount
the number of people with the condition).

 

Furthermore, the pharmaceutical collection only holds data on publicly
funded, PHARMAC subsidised drugs (all of which can be found in the
following [1]schedule) and I do not believe that

golumimab, vedoluzimab are PHARMAC subsidised at this point in time so we
do not have any visibility of their dispensings.

 

This means that I can provide the number of patients by ethnicity for
infliximab and adalumimab between 2016 and 2020 but it would not
specifically be for Crohn’s disease patients.

 

Is that okay?

 

Let me know if you have any other questions.

 

Ngâ mihi,

 

Sean Carroll

Information Analyst

Data Services

Ministry of Health

 

 

 

------------------------------------------------------------------------

From: John Mayberry <[2][FYI request #15823 email]>
Sent: Thursday, 17 June 2021 22:55
To: OIA Requests <[3][email address]>
Subject: Official Information request - Treatment of inflammatory bowel
disease by biologics

 

Dear Ministry of Health,
Total number of patients with Crohn's disease of ulcerative colitis to
receive biologic treatments (infliximab, adalumimab, golumimab,
vedoluzimab or a biosimilar) between 2016 and 2020 inclusive who were 1.
White New Zealander 2. Maori  3.South Asian by each ethnicity separately.

Yours faithfully,
John Mayberry
Professor of Gastroenterology Leicester UK

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[4][FYI request #15823 email]

Is [5][Ministry of Health request email] the wrong address for Official Information
requests to Ministry of Health? If so, please contact us using this form:
[6]https://scanmail.trustwave.com/?c=15517&...

Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
[7]https://scanmail.trustwave.com/?c=15517&...

If you find this service useful as an Official Information officer, please
ask your web manager to link to us from your organisation's OIA or LGOIMA
page.

-------------------------------------------------------------------

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

--------------------------------------------------------------------------

This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway

--------------------------------------------------------------------------

References

Visible links
1. https://schedule.pharmac.govt.nz/Schedul...
2. mailto:[FYI request #15823 email]
3. mailto:[email address]
4. mailto:[FYI request #15823 email]
5. mailto:[Ministry of Health request email]
6. https://scanmail.trustwave.com/?c=15517&...
7. https://scanmail.trustwave.com/?c=15517&...

hide quoted sections

Kia ora John,

Please find attached the requested data.
Note that the bolded and highlighted total figures may not be equal to the sum of their respective row or column since these e.g. a person my have been dispensed both infliximab and adalumimab and the totals are specifically calculated to not count this person twice in this instance.
This is also noted in the notes at the top of the data.

Let me know if there is any thing else that I can do for you.

Ngā mihi,

Sean Carroll
Information Analyst
Data Services
Ministry of Health

-----Original Message-----
From: John Mayberry <[FOI #15823 email]>
Sent: Wednesday, 23 June 2021 9:21 am
To: Sean Carroll <[email address]>
Subject: RE: Official Information request - Treatment of inflammatory bowel disease by biologics

Dear Sean Carroll,

Yes that would be very helpful
Thank you

Yours sincerely,

John Mayberry

-----Original Message-----

Kia ora John,

 

I am Sean from the data services team at the Ministry of Health, and I will do my best to help with this query.

We are the team responsible for extracting data from the national collections (including the pharmaceutical collection). We discussed your request with the OIA team and agreed that it would be best to treat this as a usual data request as it would be nice to get some more information from you.

 

I should mention that the Ministry of Health has no access to primary healthcare data so we have no way to identify if an individual has with Crohn's disease of ulcerative colitis, the only possible way to identify people with this condition would be if an individual had been hospitalised for it (and it is my understanding that this would definitely undercount the number of people with the condition).

 

Furthermore, the pharmaceutical collection only holds data on publicly funded, PHARMAC subsidised drugs (all of which can be found in the following [1]schedule) and I do not believe that

golumimab, vedoluzimab are PHARMAC subsidised at this point in time so we do not have any visibility of their dispensings.

 

This means that I can provide the number of patients by ethnicity for infliximab and adalumimab between 2016 and 2020 but it would not specifically be for Crohn’s disease patients.

 

Is that okay?

 

Let me know if you have any other questions.

 

Ngâ mihi,

 

Sean Carroll

Information Analyst

Data Services

Ministry of Health

 

 

 

------------------------------------------------------------------------

From: John Mayberry <[2][FYI request #15823 email]>
Sent: Thursday, 17 June 2021 22:55
To: OIA Requests <[3][email address]>
Subject: Official Information request - Treatment of inflammatory bowel disease by biologics

 

Dear Ministry of Health,
Total number of patients with Crohn's disease of ulcerative colitis to receive biologic treatments (infliximab, adalumimab, golumimab, vedoluzimab or a biosimilar) between 2016 and 2020 inclusive who were 1.
White New Zealander 2. Maori  3.South Asian by each ethnicity separately.

Yours faithfully,
John Mayberry
Professor of Gastroenterology Leicester UK

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[4][FYI request #15823 email]

Is [5][Ministry of Health request email] the wrong address for Official Information requests to Ministry of Health? If so, please contact us using this form:
[6]https://scanmail.trustwave.com/?c=15517&...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
[7]https://scanmail.trustwave.com/?c=15517&...

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

This e-mail message has been scanned for Viruses and Content and cleared by the Ministry of Health's Content and Virus Filtering Gateway

--------------------------------------------------------------------------

References

Visible links
1. https://scanmail.trustwave.com/?c=15517&...
2. mailto:[FYI request #15823 email]
3. mailto:[email address]
4. mailto:[FYI request #15823 email]
5. mailto:[Ministry of Health request email] 6. https://scanmail.trustwave.com/?c=15517&...
7. https://scanmail.trustwave.com/?c=15517&...

-------------------------------------------------------------------
Please use this email address for all replies to this request:
[FOI #15823 email]

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://scanmail.trustwave.com/?c=15517&...

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

*************************************************************************************
This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway
*************************************************************************************

hide quoted sections